Clinical efficacy of cetuximab combined FOLFOX chemotherapy treatment on colon and colorectal cancer
10.3760/cma.j.issn.1008-6315.2014.02.024
- VernacularTitle:西妥昔单抗联合FOLFOX方案治疗结直肠癌的临床效果
- Author:
Liping LI
;
Jinsong LIU
- Publication Type:Journal Article
- Keywords:
Cetuximab;
Colon and colorectal cancer;
FOLFOX chemotherapy
- From:
Clinical Medicine of China
2014;30(2):190-192
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of cetuximab combined FOLFOX chemotherapy on colon and colorectal cancer.Methods Forty patients with colon and colorectal cancer were randomly divided into observation group and control group,and 20 cases for each group.Patients in control group were treated with oxaliplatin + leucovorin + 5-fluorouracil,and in the observation group were given cetuximab (the first does was 400 mg/m2 at the first week,then the second week and follow weeks was 250 mg/m2 1 time/week for 6 week) plus the treatment as control group.The clinical efficacy,adverse effect and 1-year survival in the two groups were recorded.Results The total effective rate and clinical benefit rate in observation group were 60％ (12/20)and 85％ (17/20) respectively,which significantly higher than the control group (30％ (6/20) and 65 ％ (13/ 20),x2 =18.18,10.67,P ＜ 0.05).Skin rash rate in observation group was 55％ (11/20),which was significantly higher than that of control group (15％ (3/20),x2 =35.16,P ＜0.05).Half-year survival rate and 1-year survival rate of patients in observation group were 75％ (15/20) and 45％ (9/20) respectively,significantly higher than the control group (50％ (10/20) and 25％ (5/20),x2 =13.33,8.791,P ＜ 0.05)~ Conclusion Treatment scheme of Cetuximab combined FOLFOX chemotherapy is proved to be an effect of treating advanced colon and colorectal and be with the low adverse effect.
